Titan Securities Ltd. has closed its trading window for all Directors, Promoters, Key Managerial Personnel (KMPs), and other designated persons effective July 1, 2026. This measure is implemented to comply with the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal code of conduct aimed at preventing insider trading. The restriction ensures that no insider trading occurs while the company is in possession of unpublished price-sensitive information related to its financial performance.

The trading window will remain shut until 48 hours after the unaudited financial results for the quarter ended June 30, 2026, are officially declared to the stock exchanges and made public. This blackout period applies to all designated persons, including employees and their immediate relatives, to maintain market integrity and transparency. The company has stated that the specific date for the board meeting, where these results will be considered, will be communicated in due course.

Regulatory Compliance and Governance

The closure of the trading window is a standard regulatory requirement mandated by SEBI to prevent the misuse of unpublished price-sensitive information. By adhering to these regulations, Titan Securities aims to uphold fair trading practices and protect the interests of its shareholders. The company's code of conduct for the prevention of insider trading outlines strict protocols for monitoring and reporting trades by designated persons.

The communication regarding the trading window closure was addressed to the Corporate Services Department of BSE Ltd. and signed by Akansha Sharma, the Company Secretary and Compliance Officer of Titan Securities. The filing confirms that the company is taking necessary steps to ensure compliance with all applicable regulatory frameworks during the financial reporting period.

Titan Securities reported a consolidated net profit of ₹1,245.57 lakh for the financial year ended March 31, 2026, an increase from ₹1,047.36 lakh in the previous year. The Board of Directors approved the audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, at a meeting held on May 30, 2026. The statutory auditors, M/s. Goyal Nagpal & Co., issued an audit report with an unmodified opinion on the results.

The Board accepted the resignation of Mrs. Darshana Santoshi from the position of Chief Financial Officer (KMP) effective from the close of business hours on May 30, 2026, due to personal reasons. Additionally, the Board appointed Mr. Pankaj Kumar Gupta, a Practicing Company Secretary, as the scrutinizer to conduct the voting process for the 34th Annual General Meeting scheduled for 2026.

Financial Performance

The company's total revenue from operations for the year ended March 31, 2026, stood at ₹596.32 lakh on a consolidated basis, down from ₹1,042.23 lakh in the previous year. For the quarter ended March 31, 2026, total revenue from operations was ₹280.85 lakh. The profit before tax for the year was ₹113.56 lakh, while the profit after tax was ₹83.55 lakh on a standalone basis.

Consolidated Results

The consolidated results include the financial performance of associate companies, Titan Biotech Limited and Peptech Biosciences Limited. The share in profit of associates for the year amounted to ₹1,162.02 lakh, significantly contributing to the total consolidated profit. The total comprehensive income for the period was ₹1,242.40 lakh for the year ended March 31, 2026.

Key Financial Metrics (Consolidated)

The management noted a change in the measurement basis of the investment in Peptech Biosciences Ltd. from fair value to cost, following a reassessment of strategic intent. The financial statements were prepared in compliance with Indian Accounting Standards (Ind AS).